0) revealed frequent losses (mean 9 per patient) involving key hematological oncogenes (RB1, IKZF1/2/3, ETV6, NR3C1, CDKN2A/B, TP53) and immune response genes (IFNGR, TGFB, CLEC4C, IFNA cluster). Various markers suggest an AS-DC origin, but not in all patients, and some of these abnormalities are related to the leukemogenesis process, such as the 9p deletion, leading to decreased expression of genes encoding type I interferons. In addition, the AS-DC profile is only found in a subgroup of patients. Overall, the cellular ontogenic origin of BPDCN remains to be characterized, and these results highlight the heterogeneity of BPDCN, with a risk of a diagnostic trap.Luspatercept (Reblozyl) was recently approved for treating patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS) and/or SF3B1 mutation who were not eligible for erythropoiesis-stimulating agents (ESAs) or patients for whom those agents failed. Luspatercept acts as an activin receptor type IIB fusion protein ligand trap that targets the altered transforming growth factor beta pathway in MDS, which is associated with impaired terminal erythroid maturation. Treatment with luspatercept results in decreased SMAD signaling, which enables erythroid maturation by means of late-stage erythroblast differentiation and thus improves anemia. ESAs, the current standard first-line therapeutic option for anemic lower-risk patients with MDS, also improve red cell parameters mainly by expanding proliferation of early erythroid progenitor cells. However, erythropoietin (EPO) and its receptor (EPO-R) are also required for survival of late-stage definitive erythroid cells, and they play an essential role in promoting proliferation, survival, and appropriate timing of terminal maturation of primitive erythroid precursors. Thus, luspatercept joins the mechanism of ESAs in promoting erythroid maturation. Especially in the subgroup of MDS patients with RS, luspatercept showed high clinical activity for the treatment of anemia in the phase 2 (PACE-MDS) trial and subsequently in the phase 3 (MEDALIST) trial, which resulted in approval by both the US Food and Drug Administration and the European Medicines Agency in April 2020. Additional studies are needed to better understand the mechanism of action and pharmacodynamics of this novel agent in MDS.Ischemic stroke is a leading cause of morbidity and mortality worldwide and, despite reperfusion either via thrombolysis or thrombectomy, stroke patients often suffer from lifelong disabilities. These persistent neurological deficits may be improved by treating the ischemia/reperfusion (I/R) injury that occurs following ischemic stroke. There are currently no approved therapies to treat I/R injury, and thus it is imperative to find new targets to decrease the burden of ischemic stroke and related diseases. Platelets, cell fragments from megakaryocytes, are primarily known for their role in hemostasis. More recently, investigators have studied the nonhemostatic role of platelets in inflammatory pathologies, such as I/R injury after ischemic stroke. In this review, we seek to provide an overview of how I/R can lead to platelet activation and how activated platelets, in turn, can exacerbate I/R injury after stroke. We will also discuss potential mechanisms by which platelets may ameliorate I/R injury.Motion perception is a critical function of the visual system. In a three-dimensional environment, multiple sensory cues carry information about an object's motion trajectory. Previous work has quantified the contribution of binocular motion cues, such as interocular velocity differences and changing disparities over time, as well as monocular motion cues, such as size and density changes. However, even when these cues are presented in concert, observers will systematically misreport the direction of motion-in-depth. Although in the majority of laboratory experiments head position is held fixed using a chin or head rest, an observer's head position is subject to involuntary small movements under real-world viewing conditions. Here, we considered the potential impact of such "head jitter" on motion-in-depth perception. We presented visual stimuli in a head-mounted virtual reality device that facilitated low latency head tracking and asked observers to judge 3D object motion. We found performance improved when we updated the visual display consistent with the small changes in head position. When we disrupted or delayed head movement-contingent updating of the visual display, the proportion of motion-in-depth misreports again increased, reflected in both a reduction in sensitivity and an increase in bias. Our findings identify a critical function of head jitter in visual motion perception, which has been obscured in most (head-fixed and non-head jitter contingent) laboratory experiments. Inflammatory bowel disease affects all aspects of life, yet little is known about the impact of the condition on intimacy and sexuality, and if such concerns should be discussed with healthcare professionals. This hermeneutical phenomenological study aimed to explore the experiences of people living with inflammatory bowel disease discussing their sexuality concerns with healthcare professionals. Participants (n=43) aged 17-64 years were recruited. https://www.selleckchem.com/ Data were collected via in depth interviews and anonymous narrative accounts (Google Forms). Thematic analysis was used to analyze the data. An overarching theme These discussions aren't happening with four main themes were generated. The main themes were I can't image talking about sex; I am a person not my IBD; We need to talk about sex, and Those who talked about sex, talked badly. Participants described the lack conversations with their healthcare professionals on sexual wellbeing issues, in spite of the importance they gave to the topic, and identified barriers to having such conversations. They made suggestions for future clinical practice that would better meet their needs. The few who had discussed sexual wellbeing issues with healthcare professionals reported negative experiences. Patients' needs and preferences about addressing concerns related to their sexual well-being during clinical appointments should be addressed routinely and competently by healthcare professionals. Understanding the implications of inflammatory bowel disease on intimate aspects of the lives of those living with the condition could improve the quality of the care provided. Patients' needs and preferences about addressing concerns related to their sexual well-being during clinical appointments should be addressed routinely and competently by healthcare professionals. Understanding the implications of inflammatory bowel disease on intimate aspects of the lives of those living with the condition could improve the quality of the care provided.